Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer’s Disease: A 24-Week, Open-Label, Multicenter Study in Japan | August 2019

Articles

Dementia and Geriatric Cognitive Disorders Extra

https://doi.org/10.1159/000501364

Efficacy and Tolerability of Rivastigmine Patch Therapy in Patients with Mild-to-Moderate Alzheimer’s Dementia Associated with Minimal and Moderate Ischemic White Matter Hyperintensities: A Multicenter Prospective Open-Label Clinical Trial | August 2017

Articles

PLOS ONE

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0182123

The CITIMERIVA Study: CITIcoline plus MEmantine plus RIVAstigmine in Older Patients Affected with Alzheimer’s Disease | January 2021

Abstracts

Clinical Drug Investigation

https://link.springer.com/article/10.1007/s40261-020-00996-2

Risk of Rhabdomyolysis with Donepezil Compared with Rivastigmine or Galantamine: A Population-Based Cohort Study | September 2019

Articles

Canadian Medical Association Journal

https://doi.org/10.1503/cmaj.190337

Comparison of the Effects of Transdermal and Oral Rivastigmine on Cognitive Function and EEG Markers in Patients with Alzheimer’s Disease | July 2014

Articles

Frontiers in Aging Neuroscience

https://www.frontiersin.org/articles/10.3389/fnagi.2014.00179/full

Evaluation of Donepezil and Rivastigmine Administration on the Cognitive Deficits Induced by Electroconvulsive Therapy: A Randomized, Double-Blind Clinical Trial | November 2019

Articles

Family Medicine and Primary Care Review

https://www.termedia.pl/Evaluation-of-donepezil-and-rivastigmine-administration-on-the-cognitive-deficits-induced-by-electroconvulsive-therapy-A-randomized-double-blind-clinical-trial,95,37865,0,1.html

A Prospective Study on the Use of Rivastigmine Transdermal Patch in Alzheimer’s Dementia in a Routine Clinical Setting | July 2010

Articles

Dementia and Neuropsychologia

https://doi.org/10.1590/s1980-57642010dn40300014

Response of Patients with Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression | March 2001

Articles

JAMA Neurology

https://jamanetwork.com/journals/jamaneurology/fullarticle/778871

One-Year Persistence with Donepezil, Memantine, and Rivastigmine in More than 66,000 Elderly Patients Followed in Poland | August 2019

Abstracts

Journal of Alzheimer’s Disease

https://doi.org/10.3233/jad-190508

Effectiveness of Rivastigmine on Positive, Negative, and Cognitive Symptoms of Schizophrenia: A Double-Blind Clinical Trial | September 2016

Articles

NCBI>Therapeutic Advances in Psychopharmacology

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036138/

Safety and Efficacy of Rivastigmine in Adolescents with Down Syndrome: A Preliminary 20-Week, Open-Label Study | January 2007

Articles (Manuscripts-Versions)

PubMed Central>Journal of Child and Adolescent Psychopharmacology

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3129997/

A 24-Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 Mg/24 H versus 4.6 Mg/24 H in Severe Alzheimer’s Dementia | August 2013

Articles

CNS Neuroscience and Therapeutics

http://onlinelibrary.wiley.com/doi/10.1111/cns.12158/full

A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia | May 2018

Abstracts

Clinical Neuropharmacology

https://doi.org/10.1097/wnf.0000000000000275

Effect of Rivastigmine as an Adjunct to Usual Care with Haloperidol on Duration of Delirium and Mortality in Critically Ill Patients: A Multicentre, Double-Blind, Placebo-Controlled Randomised Trial (Meetings-Events) | March 2011

Abstracts

Critical Care-International Symposium on Intensive Care and Emergency Medicine

https://ccforum.biomedcentral.com/articles/10.1186/cc9759

Efficacy of 13.3mg/24h versus 4.6mg/24h Rivastigmine Patch on Activities of Daily Living in Severe Alzheimer’s Disease | December 2014

Articles

SAGE Open Medicine

http://journals.sagepub.com/doi/10.1177/2050312114561569

A Pilot Study of Rivastigmine in the Treatment of Delirium After Stroke: A Safe Alternative | September 2008

Articles

BMC Neurology

http://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-8-34

A Case Report on Dyskinesia Following Rivastigmine Patch 13.3mg/24 Hours for Alzheimer’s Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors | August 2015

Articles

Medicine

https://journals.lww.com/md-journal/Fulltext/2015/08040/A_Case_Report_on_Dyskinesia_Following_Rivastigmine.11.aspx

Real-World Utilisation of the Rivastigmine Transdermal Patches Accompanying the Use of Risk Minimisation Tools in Patients with Dementia | September 2021

Abstracts

Current Alzheimer Research

https://doi.org/10.2174/1567205018666210716120540

Domperidone Effective in Preventing Rivastigmine-Related Gastrointestinal Disturbances in Patients with Alzheimer’s Disease | September 2013

Articles

Neuropsychiatric Disease and Treatment

https://www.dovepress.com/domperidone-effective-in-preventing-rivastigmine-related-gastrointesti-peer-reviewed-article-NDT

Rivastigmine in Chinese Patients with Subcortical Vascular Dementia | January 2007

Articles

Neuropsychiatric Disease and Treatment

https://www.dovepress.com/rivastigmine-in-chinese-patients-with-subcortical-vascular-dementia-peer-reviewed-article-NDT

EXACT: Rivastigmine Improves the High Prevalence of Attention Deficits and Mood and Behaviour Symptoms in Alzheimer’s Disease | May 2007

Articles

International Journal of Clinical Practice

http://dx.doi.org/10.1111/j.1742-1241.2007.01387.x

Clinical and Cost-Effectiveness of Donepezil, Rivastigmine and Galantamine for Alzheimer’s Disease | March 2001

Publications (Books-Reports)

National Institute for Health Research

https://doi.org/10.3310/hta5010

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer’s Disease | June 2011

Articles

Dementia and Geriatric Cognitive Disorders Extra

http://dx.doi.org/10.1159/000328745

Skinfold Thickness for Rivastigmine Patch Application in Alzheimer’s Disease | January 2019

Abstracts

Psychopharmacology

https://link.springer.com/article/10.1007/s00213-018-5135-x

Evaluation of the Cardiovascular and Subjective Effects of Rivastigmine in Combination with Methamphetamine in Methamphetamine-Dependent Human Volunteers | September 2008

Articles

International Journal of Neuropsychopharmacology

https://doi.org/10.1017/S1461145708008456

Rivastigmine in the Treatment of Patients with Alzheimer’s Disease | June 2007

Articles

Neuropsychiatric Disease and Treatment

https://www.dovepress.com/articles.php?article_id=899

Rivastigmine for Minor Visual Hallucinations in Parkinson’s Disease: A Randomized Controlled Trial with 24 Months Follow-Up | July 2021

Articles

Brain and Behavior

https://onlinelibrary.wiley.com/doi/10.1002/brb3.2257

A Prospective Non-Interventional Study for Evaluation of Quality of Life in Patients with Alzheimer’s Disease Treated with Rivastigmine Transdermal Patch | June 2015

Articles

SAGE Open Medicine

http://journals.sagepub.com/doi/full/10.1177/2050312115587795

Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease | July 2010

Articles

CNS Neuroscience and Therapeutics

https://onlinelibrary.wiley.com/doi/10.1111/j.1755-5949.2010.00141.x

Long-Term Safety and Tolerability of Rivastigmine in Patients with Alzheimer’s Disease Switched from Donepezil: An Open-Label Extension Study | September 2008

Articles

Primary Care Companion for CNS Disorders

https://www.psychiatrist.com/pcc/neurologic/dementia/long-term-safety-tolerability-rivastigmine-patients/

Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle | March 2017

Articles

Parkinson’s Disease

https://www.hindawi.com/journals/pd/2017/6219851/

Once-Daily Transdermal Rivastigmine in the Treatment of Alzheimer’s Disease | November 2008

Articles

Drug Design, Development and Therapy

https://www.dovepress.com/articles.php?article_id=2568

Analysis of Outcome in Retrieved Dropout Patients in a Rivastigmine vs Placebo, 26-Week, Alzheimer Disease Trial | June 2003

Articles

JAMA Neurology

https://jamanetwork.com/journals/jamaneurology/fullarticle/784290

Rivastigmine Improves Dual-Task Gait Velocity in Patients with Alzheimer’s Disease | February 2021

Articles

BMC Neurology

https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-021-02098-8

QT Interval Prolongation and Torsades De Pointes with Donepezil, Rivastigmine and Galantamine | August 2020

Articles

Therapeutic Advances in Drug Safety

https://journals.sagepub.com/doi/full/10.1177/2042098620942416

The Clinical and Cost-Effectiveness of Donepezil, Rivastigmine, Galantamine and Memantine for Alzheimer’s Disease | January 2006

Publications (Books-Reports)

National Institute for Health Research

https://doi.org/10.3310/hta10010

Rivastigmine Improves Appetite by Increasing the Plasma Acyl/Des-Acyl Ghrelin Ratio and Cortisol in Alzheimer Disease | March 2018

Articles

Dementia and Geriatric Cognitive Disorders Extra

https://doi.org/10.1159/000487358

Rivastigmine Patch in Chinese Patients with Probable Alzheimer’s Disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 Mg/24 h) with Capsule (6 Mg Twice Daily) | March 2016

Abstracts

CNS Neuroscience and Therapeutics

http://onlinelibrary.wiley.com/doi/10.1111/cns.12521/abstract

Rivastigmine from Capsules to Patch: Therapeutic Advances in the Management of Alzheimer’s Disease and Parkinson’s Disease Dementia | September 2014

Articles

Primary Care Companion for CNS Disorders

http://www.psychiatrist.com/pcc/article/Pages/2014/v16n05/14r01654.aspx

The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study | February 2021

Articles

Clinical Interventions in Aging

https://doi.org/10.2147/CIA.S290055

Effects of Rivastigmine Hydrogen Tartrate and Donepezil Hydrochloride on the Cognitive Function and Mental Behavior of Patients with Alzheimer’s Disease | June 2020

Articles

NCBI>Experimental and Therapeutic Medicine

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388270/

Switching from Oral Donepezil to Rivastigmine Transdermal Patch in Alzheimer’s Disease: 20-Week Extension Phase Results | October 2010

Articles

NCBI>Primary Care Companion for CNS Disorders

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025991/

Factors Affecting Therapeutic Response to Rivastigmine in Alzheimer’s Disease Patients in Taiwan | May 2017

Articles

Kaohsiung Journal of Medical Sciences

https://www.sciencedirect.com/science/article/pii/S1607551X16302649

Quetiapine and Rivastigmine and Cognitive Decline in Alzheimer’s Disease: Randomised Double Blind Placebo Controlled Trial | April 2005

Articles

TheBMJ

https://www.bmj.com/content/330/7496/874

Rivastigmine: An Open-Label, Observational Study of Safety and Effectiveness in Treating Patients with Alzheimer’s Disease for Up to 5 Years | January 2005

Articles

BMC Geriatrics

http://bmcgeriatr.biomedcentral.com/articles/10.1186/1471-2318-5-3

Prediction of Treatment Response to Rivastigmine in Alzheimer’s Dementia | February 2004

Articles

Journal of Neurology, Neurosurgery and Psychiatry

https://jnnp.bmj.com/content/75/2/292.full

Evaluating Response to High-Dose 13.3 Mg/24 H Rivastigmine Patch in Patients with Severe Alzheimer’s Disease | February 2015

Articles

CNS Neuroscience and Therapeutics

https://onlinelibrary.wiley.com/doi/10.1111/cns.12385

Effects of the Online Computerized Cognitive Training Program BEYNEX on the Cognitive Tests of Individuals with Subjective Cognitive Impairment and Alzheimer’s Disease on Rivastigmine Therapy | February 2020

Articles

NCBI>Turkish Journal of Medical Sciences

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080370/

The Association Between Use of Rivastigmine and Pneumonia: Systematic Analysis of FDA Adverse Event Reporting System | September 2021

Abstracts

Journal of Alzheimer’s Disease

https://doi.org/10.3233/jad-210662

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease | June 2011

Articles

Dementia and Geriatric Cognitive Disorders Extra

http://dx.doi.org/10.1159/000328929